First Header Logo Second Header Logo

Lowell Hart

Concepts (204)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Combined Chemotherapy Protocols
27
2021
458
2.260
Why?
Lung Neoplasms
9
2020
414
1.040
Why?
Breast Neoplasms
12
2019
765
0.980
Why?
Small Cell Lung Carcinoma
1
2020
17
0.740
Why?
Antibodies, Monoclonal
10
2019
246
0.580
Why?
Carcinoma, Non-Small-Cell Lung
7
2012
101
0.550
Why?
Colorectal Neoplasms
6
2016
215
0.510
Why?
Aged
39
2021
10314
0.460
Why?
Taxoids
7
2018
59
0.430
Why?
Nitriles
3
2017
23
0.430
Why?
Triazoles
3
2017
14
0.430
Why?
Middle Aged
39
2021
11839
0.430
Why?
Disease-Free Survival
14
2018
317
0.390
Why?
Aged, 80 and over
23
2021
3990
0.380
Why?
Aminopyridines
4
2019
6
0.370
Why?
Purines
4
2019
22
0.370
Why?
Immunoconjugates
3
2019
9
0.360
Why?
Pyrimidines
3
2020
65
0.350
Why?
Adult
29
2019
9380
0.340
Why?
Multiple Myeloma
2
2021
20
0.310
Why?
Female
37
2021
20014
0.310
Why?
Treatment Outcome
20
2019
3306
0.300
Why?
Humans
41
2021
32113
0.300
Why?
Double-Blind Method
5
2020
525
0.280
Why?
Sirolimus
4
2014
33
0.280
Why?
Nanoparticles
2
2018
52
0.280
Why?
Receptor, erbB-2
6
2018
65
0.270
Why?
Salvage Therapy
2
2021
134
0.260
Why?
Adenocarcinoma
4
2015
308
0.250
Why?
Neoplasm Metastasis
9
2019
220
0.250
Why?
Male
29
2021
19216
0.240
Why?
Neoplasm Staging
9
2019
447
0.240
Why?
Postural Balance
1
2016
182
0.230
Why?
Pesticides
1
2016
199
0.220
Why?
Neoplasms
3
2016
728
0.220
Why?
Occupational Exposure
1
2016
232
0.220
Why?
Emigrants and Immigrants
1
2016
244
0.210
Why?
Transients and Migrants
1
2016
297
0.210
Why?
Mutation
2
2018
489
0.210
Why?
Antineoplastic Agents
4
2018
608
0.200
Why?
Maximum Tolerated Dose
6
2021
62
0.200
Why?
Receptors, Estrogen
6
2017
113
0.200
Why?
Protein Kinase Inhibitors
4
2018
85
0.190
Why?
Prostate-Specific Antigen
2
2018
62
0.190
Why?
Topotecan
1
2020
17
0.190
Why?
Proto-Oncogene Proteins p21(ras)
3
2016
14
0.180
Why?
Membrane Glycoproteins
3
2019
101
0.180
Why?
Quinazolines
5
2012
38
0.180
Why?
Benzamides
2
2018
50
0.180
Why?
Postmenopause
4
2017
430
0.180
Why?
Pyrroles
1
2020
55
0.180
Why?
Imidazoles
3
2015
91
0.170
Why?
Receptors, Progesterone
5
2017
72
0.170
Why?
Androstadienes
3
2013
17
0.170
Why?
Hispanic Americans
1
2016
940
0.170
Why?
E1A-Associated p300 Protein
1
2018
2
0.160
Why?
CREB-Binding Protein
1
2018
4
0.160
Why?
Survival Rate
8
2019
877
0.160
Why?
Urologic Neoplasms
1
2018
14
0.160
Why?
Camptothecin
5
2016
51
0.160
Why?
Drug Administration Schedule
5
2021
276
0.160
Why?
Leukopenia
1
2017
8
0.150
Why?
Carcinoma, Transitional Cell
1
2018
69
0.150
Why?
Central Nervous System Neoplasms
1
2018
29
0.150
Why?
Steroid 17-alpha-Hydroxylase
2
2015
3
0.150
Why?
Gene Expression Regulation, Neoplastic
1
2018
261
0.150
Why?
Naphthalenes
2
2015
40
0.150
Why?
Melanoma
1
2019
164
0.140
Why?
Antineoplastic Agents, Hormonal
1
2017
42
0.140
Why?
Pyrrolidinones
1
2016
5
0.140
Why?
Skin Neoplasms
1
2019
214
0.130
Why?
Glutamate Carboxypeptidase II
1
2016
7
0.130
Why?
Quinolines
1
2016
21
0.130
Why?
Drug Carriers
1
2016
21
0.130
Why?
Resorcinols
1
2015
6
0.130
Why?
Isoxazoles
1
2015
3
0.130
Why?
HSP90 Heat-Shock Proteins
1
2015
9
0.130
Why?
Quality of Life
2
2020
946
0.130
Why?
Drug Resistance, Neoplasm
2
2021
104
0.130
Why?
Receptor, IGF Type 1
1
2014
7
0.120
Why?
Organoplatinum Compounds
4
2012
46
0.120
Why?
Neoplasms, Hormone-Dependent
1
2013
9
0.120
Why?
ras Proteins
2
2012
10
0.120
Why?
Proto-Oncogene Proteins
2
2012
85
0.110
Why?
Bone Remodeling
1
2013
9
0.110
Why?
Neoplasm Recurrence, Local
3
2015
367
0.110
Why?
Bone Density Conservation Agents
1
2013
23
0.110
Why?
MAP Kinase Kinase 2
1
2012
2
0.110
Why?
Pyrimidinones
1
2012
4
0.110
Why?
Proportional Hazards Models
4
2019
753
0.110
Why?
Pyridones
1
2012
10
0.110
Why?
MAP Kinase Kinase 1
1
2012
4
0.110
Why?
Pancreatic Neoplasms
1
2013
134
0.100
Why?
Bone Neoplasms
1
2013
111
0.100
Why?
Antineoplastic Agents, Phytogenic
2
2014
37
0.100
Why?
Prognosis
4
2019
1497
0.100
Why?
Nausea
3
2018
53
0.100
Why?
Bone Density
1
2013
205
0.100
Why?
Fatigue
3
2018
85
0.090
Why?
Follow-Up Studies
4
2019
2265
0.090
Why?
Recombinant Fusion Proteins
1
2010
105
0.090
Why?
Lymphoma, B-Cell, Marginal Zone
1
2009
2
0.090
Why?
Lymphoma, Follicular
1
2009
17
0.080
Why?
Oligopeptides
2
2021
45
0.080
Why?
Disease Progression
3
2015
594
0.070
Why?
Carcinoma, Small Cell
1
2006
25
0.070
Why?
Cyclooxygenase Inhibitors
1
2006
40
0.070
Why?
Pyrazoles
1
2006
67
0.070
Why?
Sulfonamides
1
2006
67
0.070
Why?
Carcinoma, Renal Cell
1
2007
114
0.070
Why?
Dose-Response Relationship, Drug
2
2021
633
0.070
Why?
Diarrhea
2
2018
60
0.070
Why?
Carboplatin
3
2012
48
0.070
Why?
Deoxycytidine
3
2013
68
0.060
Why?
Treatment Failure
2
2018
162
0.060
Why?
Kidney Neoplasms
1
2007
201
0.060
Why?
Chemotherapy, Adjuvant
2
2017
190
0.060
Why?
Leucovorin
3
2012
24
0.060
Why?
Fluorouracil
3
2012
81
0.060
Why?
Young Adult
3
2019
2665
0.060
Why?
Case-Control Studies
1
2016
898
0.060
Why?
Pyrazines
2
2014
13
0.050
Why?
Paclitaxel
2
2012
67
0.050
Why?
North Carolina
1
2016
1538
0.050
Why?
Premedication
1
2021
13
0.050
Why?
Hematologic Diseases
1
2021
23
0.050
Why?
Time Factors
2
2017
2150
0.050
Why?
Gastrointestinal Diseases
1
2021
43
0.050
Why?
Receptors, Vascular Endothelial Growth Factor
2
2010
21
0.040
Why?
Histone Deacetylase Inhibitors
1
2018
21
0.040
Why?
Guanine
2
2007
15
0.040
Why?
Glutamates
2
2007
11
0.040
Why?
Breast
1
2017
68
0.040
Why?
Dyspnea
1
2017
33
0.040
Why?
Arthralgia
1
2017
33
0.040
Why?
Mastectomy
1
2017
64
0.030
Why?
Lymphatic Metastasis
1
2017
166
0.030
Why?
Hot Flashes
1
2017
48
0.030
Why?
Antigens, Surface
1
2016
24
0.030
Why?
New Zealand
1
2015
9
0.030
Why?
Asia
1
2015
19
0.030
Why?
Intention to Treat Analysis
1
2015
28
0.030
Why?
North America
1
2015
32
0.030
Why?
Hydroxamic Acids
1
2015
21
0.030
Why?
Australia
1
2015
72
0.030
Why?
Europe
1
2015
82
0.030
Why?
Retreatment
1
2015
41
0.030
Why?
Prednisone
1
2015
61
0.030
Why?
Indoles
1
2015
56
0.030
Why?
United States
3
2012
3976
0.030
Why?
Drug Therapy
1
2014
16
0.030
Why?
Neutropenia
1
2014
29
0.030
Why?
Anemia
1
2014
58
0.030
Why?
Incidence
1
2017
1199
0.030
Why?
Alopecia
1
2014
31
0.030
Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
1
2013
6
0.030
Why?
Receptors, Steroid
1
2013
9
0.030
Why?
Viscera
1
2013
17
0.030
Why?
Stomatitis
1
2013
18
0.030
Why?
Clinical Trials, Phase III as Topic
1
2013
30
0.030
Why?
Placebos
1
2013
63
0.030
Why?
Depression
1
2017
445
0.030
Why?
Procollagen
1
2013
7
0.030
Why?
Fractures, Spontaneous
1
2013
16
0.030
Why?
Bone Resorption
1
2013
12
0.030
Why?
Aromatase Inhibitors
1
2013
9
0.030
Why?
Exanthema
1
2013
21
0.030
Why?
Alkaline Phosphatase
1
2013
38
0.030
Why?
Multicenter Studies as Topic
1
2013
105
0.030
Why?
Collagen Type I
1
2013
42
0.030
Why?
Immunohistochemistry
1
2014
538
0.030
Why?
Anilides
1
2012
10
0.030
Why?
Albumins
1
2012
45
0.030
Why?
Epothilones
1
2012
3
0.030
Why?
Half-Life
1
2012
23
0.030
Why?
Osteogenesis
1
2013
82
0.030
Why?
Metabolic Clearance Rate
1
2012
17
0.030
Why?
Pyridines
1
2012
76
0.030
Why?
Drug Monitoring
1
2012
27
0.030
Why?
Area Under Curve
1
2012
93
0.030
Why?
Administration, Oral
1
2012
187
0.020
Why?
Clinical Trials as Topic
1
2013
301
0.020
Why?
Odds Ratio
1
2013
472
0.020
Why?
Biopsy
1
2012
259
0.020
Why?
Angiogenesis Inhibitors
1
2011
36
0.020
Why?
Randomized Controlled Trials as Topic
1
2013
510
0.020
Why?
Vascular Endothelial Growth Factor A
1
2011
112
0.020
Why?
In Situ Hybridization, Fluorescence
1
2010
40
0.020
Why?
Gene Dosage
1
2010
35
0.020
Why?
Boronic Acids
1
2009
8
0.020
Why?
Hypertension
1
2017
960
0.020
Why?
Feasibility Studies
1
2009
294
0.020
Why?
Receptors, Platelet-Derived Growth Factor
1
2007
4
0.020
Why?
Adenocarcinoma, Bronchiolo-Alveolar
1
2007
3
0.020
Why?
Carcinoma, Large Cell
1
2007
4
0.020
Why?
Piperazines
1
2007
54
0.020
Why?
Heart Failure
1
2013
639
0.020
Why?
Risk Factors
1
2015
3880
0.020
Why?
Cisplatin
1
2006
76
0.020
Why?
Adolescent
1
2014
3567
0.020
Why?
Survival Analysis
1
2006
483
0.020
Why?
Retrospective Studies
1
2010
3510
0.010
Why?
Mice
1
2006
2484
0.010
Why?
Animals
1
2006
7542
0.010
Why?
Hart's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (204)
Explore
_
Similar People (49)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_